Medipixel

About Medipixel

Medipixel, Inc. is a medical AI company specializing in advanced imaging analysis solutions for cardiovascular and cerebrovascular interventions. The company develops AI-powered software platforms that transform how clinicians diagnose and treat vascular diseases in catheterization laboratories. Medipixel's core technology applies deep learning to X-ray angiography images to provide real-time, automated vessel segmentation, lesion quantification, and functional assessments. The company's product portfolio includes MPXA, an AI-based coronary angiography analysis platform that automates vessel segmentation and lesion detection with an F1 score of 0.92; MPFFR, an angiography-derived fractional flow reserve (FFR) solution that delivers functional ischemia assessment in under 10 seconds with 0.949 AUC accuracy; and MPNeuro, a cerebrovascular analysis platform for 3D vessel reconstruction and quantitative analysis. All three products have received regulatory clearance from South Korea's Ministry of Food and Drug Safety (MFDS), with MPXA also securing FDA clearance in the United States. Medipixel's solutions integrate seamlessly into catheterization lab workflows, processing DICOM images in real-time to support clinical decision-making during procedures. The company serves interventional cardiologists, neurointerventionalists, and cardiovascular research core labs globally. With headquarters in Seoul, South Korea and a presence in Cambridge, Massachusetts, Medipixel partners with leading health systems, medical device companies including Philips, and clinical institutions across the United States, Europe, Japan, and India. The company has secured funding from prominent investors including Mirae Asset Capital, IMM Investment, and SBI Investment, positioning itself as a leader in AI-driven cardiovascular diagnostics.

Mission & Story

Clinical Focus

Medical conditions and clinical areas addressed by Medipixel.

Who It Serves

Milestones & Awards

Key Partnerships